Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis

Postmarketing Surveillance Study (as Per § 67(6) AMG [German Drug Law]) of Ventilat® Metered-dose Inhaler in Chronic Obstructive Bronchitis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02233920

Enrollment

716

Registered

2014-09-09

Start date

2000-01-31

Completion date

Unknown

Last updated

2014-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Brief summary

Study to obtain further information on the tolerability and efficacy of Ventilat® metered-dose inhaler in the treatment of Chronic Obstructive bronchitis under conditions of daily practice

Interventions

DRUGVentilat® - metered dose inhaler

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* Primarily Patients of both genders older than 40 years, who suffer from Chronic Obstructive bronchitis * Only patients who have not been treated with an anticholinergic within the last year are to be considered for inclusion

Exclusion criteria

•Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Ventilat® metered dose inhaler

Design outcomes

Primary

Measure	Time frame
Change in the clinical picture	after 4 weeks

Secondary

Measure	Time frame
Assessment of efficacy by investigator on a 4-point scale	after 4 weeks
Assessment of efficacy by patient on a 4-point scale	after 4 weeks
Number of patients with adverse drug reactions	up to 4 weeks
Assessment of tolerability by investigator on a 4-point scale	after 4 weeks
Assessment of patient by investigator on a 4-point scale	after 4 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026